Small Molecule vs ASO — Neurology Deal Terms Comparison
Market Analysis
In neurology, Small Molecule and ASO represent two of the most actively transacted modalities. At Phase 2, Small Molecule deals carry a median total deal value of $3.0B with $343M upfront, compared to $3.5B total value and $389M upfront for ASO. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Small Molecule development milestones average $890M versus $1.0B for ASO. Commercial milestones are $836M for Small Molecule and $963M for ASO. Royalty rates range from 12.4%-19.8% for Small Molecule and 12.9%-20.6% for ASO.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Small Molecule and ASO deal terms compare in neurology?
Which modality commands higher royalty rates: Small Molecule or ASO?
How do milestone structures differ between Small Molecule and ASO?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.